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71.  Introduction 
1.1 Haemostasis
The haemostatic process is activated as a response to vascular injury and aims at restoring 
vascular patency. It involves interactions between endothelium, platelets and coagulation 
factors. In “primary haemostasis” a vasoconstriction of the damaged blood vessel reduces the 
blood flow transiently, and platelets adhere to the site of injury to form a haemostatic platelet 
plug. In “secondary haemostasis” a stable platelet plug is formed. A cascade of enzymatic 
reactions converts proenzymes into their active forms, leading to the formation of thrombin 
which in turn converts soluble fibrinogen into a fibrin network stabilising the platelet plug. 
Fibrinolysis is triggered by fibrin which leads to the formation of plasmin. This enzyme may 
reduce and eventually break down the clot. 
1.2 Thrombosis
Thrombosis is the formation of insoluble material within the lumen of a blood vessel. This 
obstructs the blood flow, which may be particularly serious when the thrombosis completely 
occludes the lumen. Thrombosis involves the same reactions as are involved in haemostasis: 
activation of platelets and coagulation. Arterial thrombosis most often develops on 
pathologically changed intima of the vascular wall. Venous thrombosis most often occurs in 
stagnant blood and without obvious changes in intima. Venous thromboembolism (VTE) 
comprises deep vein thrombosis (DVT) and pulmonary embolism (PE). 
1.3 Activation of coagulation 
Blood coagulation has traditionally been described as a cascade [1] or waterfall [2] of an 
ordered series of enzymatic reactions that involved two different activation pathways, the 
intrinsic (contact activation) and the extrinsic (tissue factor (TF)) induced pathways meeting 
in a common pathway (for review see [3]). The understanding of coagulation is now changing 
and it has been become clear that these models do not accurately reflect the processes of 
coagulation in vivo.
8The cell based model of coagulation 
In vivo the coagulation reactions occur on cell surfaces in three distinct but overlapping 
phases: initiation, amplification and propagation [4-6]. The cellular localisation is an 
important control mechanism to keep coagulation localised to the site of injury. 
The initiation phase of the TF coagulation pathway is triggered when factor VII (FVII) binds 
to TF-bearing cells that are exposed to circulating blood as a result of vessel wall injury 
(Figure 1a). TF is an integral membrane protein and is constitutively expressed in different 
cell types such as fibroblasts and epithelial cells [7] and is normally not in contact with the 
blood stream. In severe disease states, TF may be expressed on the surface of activated 
monocytes and may trigger coagulation [8]. TF is also involved in inflammation, angiogenesis 
and tumour metastasis [9,10]. Small amounts of FVII circulate in blood as an active serine 
protease (FVIIa) [11]. The formation of TF-FVIIa complex promotes activation of the TF-
FVII complex by proteolytic cleavage of the zymogen FVII into the active enzyme FVIIa. 
The TF-FVIIa complex then converts small amounts of factors IX (FIX) [12] and X (FX) to 
their active forms (FIXa and FXa) on the cell surface. In plasma, FXa is rapidly inactivated by 
antithrombin (AT) or by tissue factor pathway inhibitor (TFPI) whereas FIXa is more stable 
and can dissociate from the cell surface to a nearby platelet. Factor V (FV) can be activated 
by FXa [13]. FXa that remains on the cell surface can combine with activated FV (FVa) to 
form the prothrombinase complex to produce small amounts of thrombin. The small amount 
of thrombin generated on TF-bearing cells also activates nearby platelets [14], exposing 
receptors and binding sites for activated clotting factors. 












9The amplification phase takes place on the phospholipid surface of the platelets at the site of 
vascular injury (Figure 1b). FV and factor VIII (FVIII) are procofactors which are converted 
into their active forms by thrombin or FXa [13,15]. Prior to activation FVIII circulates bound 
to von Willebrand factor (vWF), but activation promotes dissociation of the FVIII/vWF 
complex. Activated platelets release FV from α granules onto their surfaces. Factor XI (FXI) 
is also activated on the platelet surface by thrombin to its active form FXIa [16]. 
Figure 1b. Amplification phase. Cell based model of coagulation. 
In the propagation phase procoagulant complexes assembles on the surface of activated 
platelets to accelerate thrombin generation (Figure 1c). FIXa binds to FVIIIa to form the 
tenase complex which activates FX. The FXIa can provide additional FIXa for the formation 
of FXa. FXa associates with platelet surface FVa to form the prothrombinase complex. 
Prothrombin is then converted to prothrombin fragments 1+2 (F1+2) and a burst of thrombin 

















Figure 1c. Propagation phase. Cell based model of coagulation. 
1.4 Regulation of coagulation 
In normal haemostasis there is a natural balance between procoagulant and anticoagulant 
forces. Various inhibitory mechanisms prevent the coagulation process beyond the site of 
vascular injury that may otherwise result in thrombosis. The coagulation process is controlled 
by three inhibitory pathways: the AT pathway, the protein C (PC) pathway and the inhibition 
of TF by TFPI (Figure 2). 

































The antithrombin (AT) pathway
AT is the main inhibitor of thrombin [17] circulating at a high concentration (2.5 μM) in 
blood plasma. It is a powerful anticoagulant molecule. FXa, FIXa [18] and FXIa [19] 
generated during activation of the clotting process are also inactivated by AT. AT is a 
glycoprotein of approximately 58 kD which is synthesised in the liver [20]. Circulating AT 
molecules have slow inhibitory activity, but are accelerated considerably by specific 
interactions with glycosaminoglycans (GAG) such as heparin and heparan sulphate [21]. In
vivo AT might localise to heparan sulphate chains on the endothelium or bind to the localised 
release of heparin. Heparin may be released from the granules of mast cells which are found 
lining the vasculature. Binding of a specific pentasaccharide sequence in heparin induces a 
conformational change in the AT molecule [22] (Figure 3). 
Figure 3. Inactivation of factor Xa and thrombin by AT and heparin. AT undergoes a 
conformational change upon interaction with a specific pentasaccharide fragment in heparin 
(left). This accelerates interaction with FXa via the reactive centre loop (RCL). Interaction 
with thrombin requires heparin chains long enough to bridge AT and thrombin. Adopted with 
permission from Huntington et al [23]. 
This sequence is present in about one percent of the heparan sulphate in the vessel wall and 
about one third of mast cell heparin [24]. The change in structure of AT substantially 
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accelerates the interaction with serine proteases such as FXa and FIXa [25], but not thrombin. 
Rapid inhibition of thrombin requires heparin chain lengths of at least 18 monosaccharides 
which contain the pentasaccharide sequence. A ternary complex must be formed between 
heparin, AT and thrombin [26]. This may accelerate the interaction of AT with thrombin up to 
a thousand fold [27]. 
Heparin cofactor II 
Heparin cofactor II (HCII) contributes to the inhibition of thrombin, but its physiological 
function remains unclear [28]. Thrombin inhibition by HCII is accelerated and enhanced by 
GAGs. The GAG specificity however, is much less discriminating than that of AT. HCII is 
activated by dermatan sulphate, heparin, and heparan sulphate [29]. In comparison with AT, 
much higher concentrations of heparin or heparan sulphate are necessary to activate HCII 
[30]. The heparin binding mechanism of HCII is similar to that of AT [31]. HCII is 
synthesised in the liver and the mature protein is approximately 66 kD. Like AT, HCII 
circulates at a high concentration in plasma (1.2 μM) [32]. 
The protein C (PC) anticoagulant pathway 
The PC system is an effective and important way of regulating the activities of the cofactor 
FVIIIa in the tenase complex, and the cofactor FVa in the prothrombinase complex. In 
addition to anticoagulant properties PC also has anti-inflammatory and antiapoptotic 
properties [33]. PC is synthesized in the liver with a MW of approximately 62 kD [34]. It 
circulates in the blood as a zymogen. Binding of thrombin to its cofactor thrombomodulin 
(TM) on the endothelial cell surface changes the enzymatic specificity of thrombin and 
activates PC by enzymatic cleavage [35]. The endothelial PC receptor helps to orient PC to 
the thrombin-TM complex and provides further stimulation of the activation of PC [36]. 
Activated PC (APC) inhibits coagulation by inactivating surface bound FVa and FVIIIa [37]. 
The anticoagulant activity of APC is supported by free protein S (PS) which functions as a 
cofactor for APC in the degradation of FVa [38]. Degradation of FVIIIa by APC requires 
cofactor activities of both PS and FV [39]. APC is a specialised enzyme and cleaves FVa in 
three sites at positions Arg306, Arg506 and Arg679 [40]. The Arg506 cleavage is kinetically 
favoured over the Arg306 cleavage. 
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Inhibition by tissue factor pathway inhibitor (TFPI)
TFPI is a plasma serine protease inhibitor. Inactivation of the TF-FVIIa complex by TFPI is 
dependent on FXa and involves a formation of a quaternary complex containing FXa-TFPI-
TF-FVIIa [41]. TFPI consists of three Kunitz-type domains followed by a long carboxy-
terminus [42]. The first Kunitz domain interacts with FVIIa and the second domain binds FXa 
[41]. TFPI recognises FXa most effectively when the enzyme is in the prothrombinase 
complex [43]. Once this occurs, FXa can only be produced by the tenase complex. TF-FVIIa 
may also be inactivated by AT-heparin complex [44], but inactivation by TFPI is the main 
physiological inactivation mechanism. 
In plasma TFPI exists both in full-length and variably carboxy-terminated truncated forms. 
TFPI is mainly produced by microvascular endothelial cells and the total normal plasma 
concentration is 1.0-2.5 nM [45,46]. The major fraction of circulating TFPI is bound to 
lipoproteins, in particular low-density lipoproteins [47]. The most predominant forms of 
plasma TFPI have a molecular weight of 34-41 kD [48].
1.5 Disseminated intravascular coagulation (DIC) 
DIC is an acquired disorder characterised by systemic activation of blood coagulation and 
subsequent exhaustion of anticoagulation mechanisms and the fibrinolytic system. In its 
fulminant form, this may lead to simultaneous widespread microvascular thrombosis and 
profuse bleeding from various sites [49]. Ongoing activation of coagulation leading to 
vascular fibrin deposition, thereby compromising an adequate blood supply may contribute to 
multiple organ failure. 
The mechanisms involved are TF dependent initiation of coagulation, amplification of 
thrombin generation caused by consumption of platelets, coagulation factors and inhibitors 
and propagation of fibrin deposition in the microvasculature caused by insufficient fibrin 
degradation as a result of an inhibited fibrinolytic system. 
DIC is not a disease in itself, but is always secondary to an underlying disorder. Clinical 
conditions that may be associated with DIC are severe infections, major trauma and tissue 
damage, obstetrical complications, cancer, immunological and haematological disorders [50]. 
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1.6 Thrombophilia
Thrombophilia can be defined as an increased persistent tendency to thrombosis and can be 
acquired or inherited. Inherited thrombophilia may be caused by several different genetic 
defects that mostly result in reduced levels of inhibitors of coagulation in the blood. This 
leads to a hypercoagulable state and an increased risk of VTE. The most common forms of 
venous thrombosis are DVT of the leg and PE [51]. Arterial thrombosis is only rarely 
triggered by thrombophilia. 
1.6.1 Inherited thrombophilia 
Deficiencies of the natural coagulation inhibitors AT, PC and PS are rare and can be found in 
less than 1% of the general population. Deficiencies which are associated with increased 
procoagulant activity, FV Leiden and prothrombin gene mutation are more common causes of 
inherited thrombophilia. 
Antithrombin (AT) deficiency
AT accounts for about 80% of the thrombin inhibitory activity of plasma. Inherited AT 
deficiency as a cause of familial thrombophilia was first reported in 1965 by Egeberg [52]. 
AT is a single chain glycoprotein, belonging to the serine protease inhibitor (serpin) 
superfamily. Its concentration in plasma is 2.5 μM [53]. AT deficiency is a heterogeneous 
disorder and can be classified as type I and type II. Type I heterozygous AT deficiency is 
defined as about 50% functional and antigen activity of AT, whereas type II is characterised 
by the synthesis of a variant protein with altered function. According to which function of the 
protein is affected, three type II subtypes can be defined: reactive site defect, pleiotropic 
effect (abnormal tertiary structure) and heparin binding site defect. AT deficiency is a rare 
disorder with a prevalence of type I of about 0.02% and type II of about 0.16% [54]. 
Heterozygous AT deficiency increases the risk of venous thrombosis 25-50-fold which is 
higher compared to any other thrombophilic state and is found in 1-4% of patients with 
venous thrombosis [55-57]. An exception is mutations affecting the heparin binding site 
which appear to be associated with a low risk of thrombosis [58,59]. Homozygous AT 
deficiency is probably incompatible with life except in the case of the type II defect involving 
the heparin binding site [60]. 
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Protein C (PC) and protein S (PS) deficiencies 
PC and PS deficiencies result in defects in the PC anticoagulant system leading to decreased 
inactivation of cofactors Va and VIIIa. The first report of heterozygous PC deficiency was 
published in 1981 [61]. PC is a vitamin K dependent glycoprotein. The concentration of PC in 
plasma is 65 nM. PC deficiency is classified as type I: low plasma levels of both functional 
and antigen PC and type II: low plasma levels of functional protein with normal antigen 
levels. Its prevalence is about 0.2-0.3% [62]. Heterozygous PC deficiency increases the risk of 
venous thrombosis 10-15-fold [63]. The risk of thrombosis appears not to be different for the 
different types of PC deficiency [64]. PC deficiency occurs in 3-6% of patients with venous 
thrombosis [56,57]. 
PS is a vitamin K dependent glycoprotein produced manly by hepatocytes, but also by 
endothelial cells and megacaryocytes [65-67]. The concentration of PS in plasma is 0.35 μM 
[68]. Families with PS deficiency have been reported since 1984 [69,70]. About 40% of PS 
circulates in plasma as a free protein, the remainder being bound to the complement 
regulatory protein C4b-binding protein [71,72]. There are three types of PS deficiency. Type I 
is associated with low plasma levels of both total and free PS. Type II is associated with low 
plasma levels of functional protein and normal total and free PS levels. Type III is 
characterised by normal levels of total PS and low levels of free PS and is due to mutations 
that enhance the binding of PS to C4b-binding protein. The prevalence of PS deficiency is 
0.03-0.13% [73] and occurs in 1-5% of patients with venous thrombosis [57,74]. 
Heterozygous PS deficiency increases the risk of venous thrombosis nearly 10-fold [75]. 
In persons with a deficiency of PC or PS, type I defects predominate. Homozygous PC and PS 
deficiency are associated with neonatal purpura fulminans, a syndrome characterised by 
widespread venous thromboses and acute haemorrhagic lesions in the newborn period [76]. 
Factor V (FV) Leiden mutation
The most common inherited gene defect associated with venous thrombosis is the FV Leiden 
mutation [77], which results in a phenotype called APC resistance [78]. A single point 
mutation in the FV gene (G1691A) replaces Arg506 with Gln. This results in the loss of one 
of the three APC cleavage sites in FV/FVa. The PC system is affected in two ways by the 
mutation. The first is impaired degradation of mutant FVa by APC because one of the three 
cleavage sites is missing. The second is poor degradation of FVIIIa because mutant FV is a 
poor cofactor to APC in the degradation of FVIIIa. The mutation is predominantly found in 
whites and in 20-40% of patients with venous thrombosis [79,80]. The prevalence of FV 
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Leiden in the general population varies geographically. The highest prevalence is found in 
northern Europe where 7-15% carries the mutation [81]. Heterozygous FV Leiden increases 
the risk of thrombosis about 2-5-fold [82,83] and homozygous FV Leiden increases the risk 
about 18-fold [83]. Combined thrombophilias most often involves FV Leiden and another 
abnormality because FV Leiden is relatively common. It is suggested that persons with 
combined thrombophilic defects are at a higher risk of thrombosis than those with either 
defect alone [84,85]. The high prevalence of the FV Leiden mutation might suggest a positive 
selection mechanism related to decreased pregnancy bleeding complications [86]. 
Prothrombin gene mutation
A single mutation (G20210A) in the prothrombin gene is the second most common genetic 
risk factor for thrombosis [87]. The prothrombin function is unaffected by the mutation, but 
the levels of prothrombin in plasma are increased [88]. This mutation is associated with 3-5-
fold increased risk of thrombosis [87]. Homozygosity for prothrombin gene mutation is much 
rarer and causes a higher thrombotic risk. The population prevalence of the heterozygous 
G20210A mutation among Caucasians is about 1-4% with considerable geographic variation 
[89].
1.6.2 Acquired risk factors for venous thrombosis 
In the mid-1800s, Virchow postulated three major causes of thrombosis: changes in the vessel 
wall, changes in the blood flow and increased coagulability. This triad still applies. Most of 
the risk factors for venous thrombosis (Table 1) fall into the last two groups. 
Table 1. Inherited and acquired risk factors for VTE. 
Inherited Acquired Mixed 
Antithrombin deficiency Antiphospholipid antibodies Hyperhomocysteinemia 
Protein C deficiency Cancer Elevated FVIII, FIX, FXI 
Protein S deficiency Medical disorders Acquired APC resistance 
Factor V Leiden mutation Immobilisation  
Prothrombin gene mutation Surgery/trauma  
 Pregnancy/puerperium  
 Oral contraceptives  
 Hormone therapy  
 Obesity  
 Age  
 Previous VTE  
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Antiphospholipid antibodies 
Antiphospholipid (APL) antibodies are autoantibodies directed against anionic phospholipids 
or protein-phospholipid complexes. ȕ-2 glycoprotein I is the principal target in the 
antiphospholipid syndrome (APS ) [90,91], but many other antigenic targets have been 
described including prothrombin and annexin V [92,93]. APS is a disorder that refers to 
recurrent arterial and venous thrombosis, and pregnancy loss associated with the presence of 
APL antibodies and persistently positive anticardiolipin or lupus anticoagulant (LA) positive 
tests. LAs are antibodies that block phospholipid surfaces important for coagulation. They 
reduce the coagulant potential of the plasma and prolong the clotting time in coagulation tests 
based on the activated partial thromboplastin time (APTT) [94]. APS may occur alone or in 
association with systemic lupus erythematosus (SLE). In SLE, the risk of thrombosis is 
increased in individuals with APS antibodies [95]. These abnormalities are found in about 
one-half of patients with SLE. The risk of thrombosis is also increased in patients who do not 
have SLE but do have a LA. This abnormality has been estimated on the average to lead to a 
nine-fold increase of thrombosis [96]. 
Homocysteinemia
Homocysteine is a sulphur-containing amino acid formed during the metabolism of 
methionine. Mild to moderate hyperhomocysteinemia is found in individuals with genetic 
defects, acquired conditions, or both. Acquired causes predominate and are found in patients 
with dietary deficiencies of folate, vitamin B12, or vitamin B6, while inherited forms are most 
commonly due to mutations affecting the cystatione ȕ-synthase gene or the methylene 
tetrahydrafolate reductase (MTHFR) gene [97,98]. The mechanism by which 
hyperhomocystenemia affects the risk of thrombosis is unknown [99]. While severe 
hyperhomocysteinemia is rare, mild elevations of homocysteine are present in 5-10% of the 
healthy population and is probably associated with 2-3-fold increased thrombotic risk 
[100,101].
High levels of factor VIII (FVIII) 
A dose-response relationship between FVIII levels and the risk of thrombosis has been 
observed [102,103]. Plasma FVIII levels reflect the combined influence of inherited and 
acquired factors. Relative to those people with levels below 1000 IU/l, those with levels 
above 1500 IU/l may have a 5-fold increased risk for thrombosis [102]. Increased levels of 
FVIII are quite common in the general population, with a prevalence of about 11%, while up 
18
to 25% of patients with venous thrombosis have FVIII levels higher than normal [104]. FVIII 
is an acute phase reactant. Long term elevated FVIII levels have been demonstrated to be 
independent of the acute phase response [105]. Increased levels of FIX and FXI are also 
associated with an increased risk of thrombosis [106,107]. 
Cancer
Venous thrombosis is a common complication in cancer patients. 10-20% of patients with 
venous thrombosis have cancer [108,109]. The thrombogenic effect of cancer may be the 
result of several factors. The tumour itself may increase the risk of thrombosis due to venous 
obstruction, production of procoagulants and acute phase reactions [110]. Furthermore, there 
may be less mobility due to the illness, as well as thrombogenic effects of treatment [110]. 
Cancer patients undergoing surgery have about a 2-fold increased risk of postoperative VTE 
compared to non-cancer controls undergoing the same procedures [111]. After middle age the 
prevalence of cancer in a population may be 2-3%. The incidence of symptomatic VTE in 
cancer patients has been described to be approximately 15% [112]. 
Immobilisation
Thrombosis may occur in many circumstances that are associated with immobilisation such as 
bed rest [113] and prolonged travel [114]. These situations interfere with the function of the 
musculature in pumping the blood upstream through the veins. Unless accompanied by an 
additional risk factor the absolute risk of VTE associated with immobilisation is small. 
Surgery and trauma 
Major surgery is one of the strongest risk factors for thrombosis. Without thromboprophylaxis 
surgery can lead to thrombosis in up to 50% of the patients, dependent on the type of surgery. 
VTE is often asymptomatic and high frequencies were disclosed in screening studies. In 
orthopaedic surgery of the hip and knee, the risk of thrombosis reaches 30-50% [115,116]. 
Major trauma is also an important risk factor for thrombosis and occurs in up to 50-60% of 
patients with head trauma, spinal injury and pelvic fractures [117]. After elective abdominal 
surgery, the frequency of VTE is about 20% [118]. Prophylaxis against VTE is now a routine 
in patients older than 40 years having a major operation [119]. 
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Pregnancy
About one in 1000 women will develop thrombosis during pregnancy [120,121]. When 
compared to the same age group, the risk appears about 10-fold increased. During pregnancy 
there is shift in the haemostatic balance towards a more hypercoagulable state, with increasing 
concentrations of most clotting factors and decreasing concentrations of natural 
anticoagulants [122,123]. These alterations protect pregnant women from severe haemorrhage 
during delivery. The risk of thrombosis during pregnancy is greater in women with inherited 
thrombophilia [124,125]. Pregnant women with AT deficiency appear to have an unusually 
high risk for thromboembolism, and should receive anticoagulant prophylaxis throughout 
pregnancy and puerperium [126]. Thrombophilia increases the risk of pregnancy loss 
[127,128].
Oral contraceptives 
The first association of oral contraceptive (OC) use and thrombosis was reported in 1961 by 
Jordan [129]. The increased risk of venous thrombosis was later confirmed in many reports. 
Early OCs contained 100 μg or more of oestrogen, but over the years the dose of oestrogen 
has been substantially reduced to 30 μg and even lower. The reduction in oestrogen content 
was accompanied by a reduction in risk of venous thrombosis, but even the low-dose OCs that 
are used today increase the risk of thrombosis 2-5-fold [130,131]. Oestrogens markedly affect 
the coagulation system, with increased levels of procoagulant factors and reduced 
concentrations of the anticoagulant factors PS, AT and TFPI [132,133]. Combined 
monophasic OCs that consist of a combination of oestrogen and progestogen are the most 
common birth control pills. The oestrogen content is usually ethinylestradiol, while the 
progestogen component has changed over the years, from first-generation which is no longer 
used, to second-generation (levonorgestrel), to third-generation progestogens (desogestrel, 
gestodone and drospirenone). The risk conferred by OCs is not restricted to the oestrogen 
content, but also depends on the progestogen content. Some of the effects on the coagulation 
system are more pronounced in OCs containing third-generation progestogens, than in those 
containing second-generation progestogens, leading to a more pronounced prothrombotic 
state [134-136]. Third-generation progestogen counteracts the prothrombotic effect of the 
oestrogen component less effectively compared with the second-generation progestogen. OCs 
containing the third-generation progestogens confers a 2-fold higher risk than the second-
generation OCs [137]. OCs also greatly increases the risk of thrombosis in persons with 
inherited thrombophilia [138]. 
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Hormone treatment 
Postmenopausal hormone therapy (HT) is used for treatment of symptoms of the menopause 
and to reduce the progression of osteoporosis [139]. The effective content of HT is the 
oestrogen, but since hormones with only oestrogens increases the risk of endometrial cancer it 
is common to combine oestrogen with progestogen [140]. In Scandinavia mostly oestradiol is 
used, which is natural oestrogen. Norethisterone acetate (NETA) is the most common 
progestogen used in Norway. The dose of oestrogen in HT is very low compared to OCs. Yet, 
several studies have demonstrated that HT increases the risk of thrombosis 2-4-fold 
[131,141,142]. The risk of venous thrombosis is higher shortly after therapy has started [142]. 
There has been a recent trend to use lower doses of oestrogen and progestogen for HT based 
on evidence of similar effectiveness of low-dose HT on symptoms and bone [143]. HT is 
associated with a significant dose-response dependent activation of coagulation [144]. 
Moreover HT is also associated with decreased AT, TFPI and PS concentrations and 
increased resistance to APC [145,146]. 
Raloxifene is a selective oestrogen receptor modulator (SERM). SERMs bind with high 
affinity to the oestrogen receptor and result in oestrogen agonist effects in bone tissue and the 
cardiovascular system and oestrogen antagonist effects in endometrial and breast tissue [147]. 
Women treated with raloxifene have an increased risk of venous thrombosis [148]. 
Tibolone is a synthetic steroid analogue with oestrogenic, androgenic and progestogenic 
properties depending on the target tissue involved [149]. It is used in the management of 
climacteric symptoms and bone loss. Tibolone has so far not been associated with an 
increased risk of venous thrombosis, but sufficient epidemiological and clinical data are 
missing [143]. Recently, an increased risk of stroke has been reported [150]. 
Age
One of the strongest risk factors for thrombosis is age. The risk of thrombosis increases 
sharply with age, with a 1000 fold difference in risk of thrombosis between the very young 
and the very old [151,152]. It is not clear why there is an age gradient, but plausible reasons 
are a combination of decreased mobility, decreased muscular tone, increased frequency of risk 
enhancing diseases and acquisition of other risk factors as well as aging of the veins and the 
valves in the veins. Changes in the coagulation system may also contribute to an increased 
risk of thrombosis. 
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1.6.3 Cooperative effects on risk of venous thrombosis 
Risk factors resulting from interaction between genetics, environmental factors and behaviour 
may bring about thrombosis. The combination of a genetic defect with one or more 
environmental risk factors and the combination of two environmental risk factors result in a 
risk of venous thrombosis that exceeds the sum of the separate effects of the single factors. 
Carriers of the heterozygous FV Leiden mutation have up to 30-fold increased risk of 
thrombosis when they use oral contraceptives compared with nonusers with a normal 
genotype [153,154]. The risk is higher than expected because it is not the additive effects of 
the two risks. The risk factors potentiate each other. 
1.7 Assay methods for inherited thrombophilia 
Thrombophilia was for many years investigated exclusively by means of plasma based-assays 
(phenotypic assays). More recently DNA-analysis has become available. Phenotype 
determination is more difficult to standardise and the results may be variable. For 
thrombophilic conditions such as AT, PC and PS deficiency the underlying defect may be 
attributable to several mutations and genetic testing is at present only applicable in research. 
AT, PC and PS deficiency states are nearly always heterozygous, which implies that the 
measured inhibitor activity is about 50% of normal reference. 
Antithrombin assays 
The laboratory diagnosis of AT deficiency is based on functional (qualitative) and 
immunological (quantitative) assays. Measurement of the AT antigen is not sufficient because 
it would leave dysfunctional AT deficiency with normal antigen level and reduced functional 
activity undetected. Dysfunctional AT may be investigated by running double cross-
immunoelectrophoresis [155]. 
In commercial functional assays AT can be measured in terms of its ability to inhibit either 
thrombin or FXa in the presence of heparin. Residual thrombin or FXa is measured with 
specific chromogenic substrates. These assays are easily automated and performed on 
coagulation analysers. Both AT deficiency type I and type II produce pathological results. In 
order to distinguish between them, antigen should also be measured. AT activity may also be 
measured in the absence of heparin, but this type of assay is mainly used for research 
purposes such as to further characterise type II deficiencies. 
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Protein C assays 
Functional assays are designed to measure the inhibitory activity of APC exerted against the 
natural substrates FVa or FVIIIa. This is usually assessed with APTT or using synthetic 
chromogenic substrates. PC may be activated with the snake venom Protac or thrombin-TM 
[156]. These tests are commercially available and may be easily adapted to automation. 
Antigen PC measurements may be used for further characterisation of defects identified by 
functional assays. 
Protein S assays 
The presence of both free and bound PS in plasma complicates the diagnosis of PS deficiency. 
Basically three types of assays can be recognised: immunological assays for free PS, 
immunological assays for total PS and PS functional assays. 
The functional assays that are used to assess PS are based on the APC cofactor activity of PS 
and are not very specific. They may be affected by APC resistance [157,158]. Alternatively 
PS antigen can be measured. It has been debated whether total or free antigen should be 
measured, but it appears that the free antigen is most reliable for discriminating carriers from 
noncarriers of PS deficiency [159,160]. The sensitivity (and specificity) of PS assays tend to 
be lower than for the assays of AT and PC, and normal reference ranges accordingly larger. 
APC resistance test 
APC resistance can be measured in plasma with APTT based methods with and without 
activation of PC [78]. These methods are simple and inexpensive. Heterozygous and 
homozygous FV Leiden mutation may be discriminated using APTT based methods. FV 
Leiden mutation accounts for most, but not all cases of APC resistance. An abnormal APC 
resistance test could also be due to a LA or other unknown causes. Improved ability to 
distinguish carriers from noncarriers of the FV Leiden mutation has been obtained with APTT 
based methods where test plasma is prediluted with FV-deficient plasma [161]. An abnormal 
APC resistance may be confirmed by a simple polymerase chain reaction (PCR) test [77]. 
Prothrombin gene mutation test 
PCR analysis is usually performed to detect the prothrombin G20210A mutation [87]. Plasma 
analysis for prothrombin measurement is seldom performed because it is unable to clearly 
distinguish carriers from noncarriers of the mutation. 
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1.8 Global coagulation assays 
Global coagulation tests reflect in various ways the formation of thrombin. Screening assays 
are performed in order to get an overview of the entire coagulation system including the 
interactions of enzymes, cofactors and inhibitors. Thrombin activity may be recorded most 
simply in clot-based assays, where the end point is the formation of a fibrin clot. The clotting 
time assays prothrombin time (PT) [162] and APTT [163] are clinically useful to detect 
hypocoagulability. It has so far been difficult to develop laboratory methods that globally 
measure the existence and the degree of thrombophilia in a simple way. Thrombosis is often 
multifactorial, caused by an acquired risk factor in an individual with a thrombophilic 
condition. A method that measures not only the presence of a single thrombophilic condition, 
but the combined effects of the pro and anticoagulant activity might limit the use for specific 
assays. A dynamic monitoring of the coagulation process may be obtained by measuring 
fibrin aggregation [164,165]. Another approach is to assess thrombin generation through the 
use of chromogenic or fluorescent peptide substrates [166]. 
1.8.1 Clotting time assays 
Prothrombin time (PT) 
The PT assay is performed by adding a thromboplastin or TF reagent and calcium to test 
plasma and measuring the clotting time [162]. Thromboplastins are complex mixtures 
prepared from extracts of brain or placenta. Newer thromboplastins most often contain 
recombinant TF relipidated into phospholipids. PT is prolonged with deficiencies of FVII, 
FX, FV, prothrombin and fibrinogen. It is most frequently used to monitor warfarin therapy. 
The International Normalised Ratio (INR) is used to standardise anticoagulant monitoring. It 
is used to compensate for different sensitivities of thromboplastins to factor deficiencies. The 
INR system is also used in patients with liver failure. The Owren PT procedure can be used to 
measure FVII, FX and prothrombin [167]. Adsorbed plasma is used as a source of fibrinogen 
and FV. 
Activated partial thromboplastin time (APTT) 
Originally the APTT was the coagulation time of the test plasma added exogenous 
phospholipids (cephalin) as platelet substitutes and calcium chloride [168]. It has been 
modified by the addition of activators of the contact phase of coagulation such as kaolin and 
ellagic acid [163] which shorten the clotting times. The phospholipid in this assay is called 
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partially thromboplastin because TF is absent. APTT became the test of choice to screen 
patients for congenital and acquired hemorrhagic diseases. Automated assays have replaced 
the old manual methods. The clotting times varies according to the reagent and coagulometer 
used [169]. The APTT is a global test sensitive to low levels of all the coagulation factors 
except factors FVII and FXIII. It is the test most often used to monitor unfractioned heparin 
[170]. The APTT has been extensively used to search for LA in patients with a history of 
thrombosis or fetal loss [171]. Recently it was found an association between shortened APTT 
and the risk of VTE [172]. Hypercoagulability due to high coagulation FVIII, FIX, FXI, 
prothrombin and fibrinogen may possibly be detected by the APTT. 
ProC global (PCG) 
PCG is a coagulation assay which tests the global function of the PC pathway [173]. It is a 
one stage-clotting time assay that is sensitive to deficiencies in the PC system. The 
anticoagulant response in plasma is measured by an APTT and clotting times in plasma are 
measured with and without APC. Endogenous APC is activated by the addition of the snake 
venom Protac [174] which leads to prolonged clotting times in normal plasma. The assay is 
sensitive to the FV Leiden mutation and PC deficiency. The sensitivity towards PS deficiency 
is lower, and it is not suited for the detection of AT deficiency. An advantage is that the assay 
can be performed with any automated coagulation instrument. 
1.8.2 Thrombin generation assays 
The original concept of a thrombin generation (TG) test was described in 1953 [175]. TG was 
triggered in the primary reaction tube containing plasma and clotting times were measured by 
subsampling at regular intervals into secondary indicator tubes containing fibrinogen solution. 
Measurement of TG provided a method for quantifying the effect of the procoagulant and 
anticoagulant factors that determine coagulation capacity. 
Endogenous thrombin potential (ETP): 
The principle of the TG assay was developed further by Hemker et al [176]. The fibrinogen 
solution was replaced by a thrombin specific chromogenic substrate and the primary plasma 
sample was defibrinated. A time-recording pipette linked to computerised data capture was 
added to plot generated thrombin against time. From this TG curve or thrombogram, the area 
under the curve named the ETP was calculated in addition to lag time, peak height and time to 
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peak (Figure 4). The calculation of thrombin activity was complicated by the use of a 
chromogenic substrate, which in itself influences the thrombin-decay process. Some of the 
thrombin in plasma reacts with Į2-macroglobulin to form a complex that, though biologically 
inactive, still is capable to convert small substrates. A further development of measurement of 
the ETP was the use of a slow reacting substrate, which permitted continuous registration of 
thrombin activity in the primary reaction tube [177]. With this modification, the test was fully 
automated. 
Calibrated automated thrombogram (CAT): 
The replacement of the chromogenic substrate with a slow reacting fluorogenic substrate 
[178] enabled continuous measurement of TG without the need for defibrination, as the signal 
from the fluorophore is not quenched by turbidity. This made it possible to measure TG also 
in platelet rich plasma. The absence of a direct linear relation between thrombin activity and 
the fluorescent signal is overcome in CAT by monitoring the splitting of a fluorogenic 
substrate and comparing it to a constant known thrombin activity in a parallel non-clotting 
sample. Even though this modified method in combination with a microtiter plate fluorimeter 
was an improvement, it seems that the assay system is still technically complicated. 
Figure 4. The parameters of the thrombogram. A: Lag time, B: Peak height, C: 
Endogenous thrombin potential (ETP), D: Maximal rising slope, E: Time to peak. Adopted 
with permission from Hemker et al [166] 
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1.8.3 Specialised assays 
Clot waveform analysis 
Standard clotting assays such as APTT or PT can be elaborated to provide more information 
than just the clotting time. In clot waveform analysis fibrin formation is monitored photo-
optically by measurement of the changes in light transmittance that occur as plasma clots. 
Thus, clot waveforms can be performed at the same time as the clotting end point is 
determined for the APTT and PT assays. Information on the velocity and acceleration may 
then be derived from the data. The APTT waveform analysis was found to be sensitive to very 
low levels of FVIII [179]. The degree of abnormal biphasic APTT waveforms are directly 
correlated to haemostatic dysfunction in DIC [180]. The PT waveform analysis may be 
promising for the detection of LA [181]. 
Thromboelastography (TEG) 
TEG records the viscosity and the elastic changes that occur during coagulation and provides 
a graphical representation of the fibrin polymerisation process using a specialised instrument 
[182]. The viscoelastic properties of whole blood are measured. Fibrin formation results in a 
pictorial haemostasis profile, the time taken for initiation and the kinetics of clot formation, 
the strength of the clot and its dissolution are recorded. Unlike clotting assays, TEG monitors 
haemostasis as a dynamic process. This makes it possible to study the interaction between 
platelets and the coagulation cascade and can provide information on interactions with the 
fibrinolytic systems. Hence, this method may more closely reflect the in vivo clotting 
situation.
TEG was originally designed as a bedside monitor using native whole blood. The main uses 
of TEG have been to monitor blood component therapy during surgery, primarily to detect 
haemostatic failure earlier than by conventional assays. The use of the TEG in the laboratory 
setting represents a significant change of use for the instrument. To perform tests within the 
laboratory plasma samples are used. 
In a study of pregnant women there was a correlation between TEG parameters and AT level. 
There was no relationship between TEG variables and levels of PS and PC, or the FV Leiden 
mutation, prothrombin and MTHFR genetic mutations [183]. 
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Recently, a modified TEG analysis principle with the use of whole-blood and a very low TF 
concentration to trigger the reaction was used to study hypercoagulation. A certain degree of 
hypercoagulation was detected in a group of unselected thrombosis prone patients [184]. 
In an evaluation of whole blood clotting, the thrombus generation curve as measured by the 
TEG system and the thrombin generation curve as measured by a thrombin-AT reference 
method were found to be inter-related [185]. 
Overall haemostasis potential (OHP) 
He et al developed a laboratory method in order to identify imbalances in the haemostatic 
system [164,165]. OHP in plasma was established to detect a hypercoagulable or a 
hypocoagulable state. The principle of the assay was spectrophotometric monitoring of 
opacity caused by fibrin aggregation and lysis in plasma activated by small amounts of 
thrombin, tissue-type plasminogen activator (t-PA) and calcium chloride. OHP was 
determined by calculating the area under the opacity curve (AUC). 
In their original assay the AUC reflected variations according to the concentration of added 
purified pro- and anticoagulants to examined plasma in vitro activated by 0.2 IU/ml thrombin, 
700 ng/l t-PA and 17 mM calcium chloride. Addition of AT decreased the AUC in a dose-
dependent way. 
To prevent initiation of clotting by the exogenous added thrombin the assay was modified. 
Thrombin in a decreased dose (0.04 IU/ml) with or without t-PA was added to plasma for 
initiation of fibrinogen clotting. In addition to OHP, the overall coagulation potential (OCP) 
curve, which is coagulation of plasma without t-PA was monitored. The relative difference 
between the areas under the OHP and OCP reflects the overall fibrinolysis potential (OFP) 
and is calculated as ((OCP-OHP)/OHP) x 100% (Figure 5). 
The assay detected elevated OHP levels in normal pregnancy, more elevated in preeclampsia 
and in coronary heart disease [186]. Increased OHP levels were found in patients with 
previous DVT and in patients with FV Leiden mutation [186]. To obtain an assay system 
more similar to the haemostasis balance in vivo OHP was further modified by introducing a 
platelet reagent containing TF and phospholipids. The authors reported extremely low or 
undetectable levels of OHP and OCP in samples of F VIII-, IX-, VII-, V-, X- or II-deficient 
plasma, showing an improved power to identify hypocoagulability [187]. 
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Figure 5. Overall haemostasis potential (OHP), overall coagulation potential (OCP) and 
overall fibrinolysis potential (OFP) assayed in normal plasma. Adopted with permission 
from He et al [165]. 
Recently a modification of the global assay described by He et al [164,165] and Smith et al 
[188] was presented by Goldenberg et al [189]. The Clot Formation and Lysis assay 
(CloFAL) simultaneously measures coagulation and fibrinolytic capacities in plasma after 
addition of trace amounts of calcium, TF and t-PA. Absorbance of clot formation and lysis are 
monitored for three hours and the AUC is calculated in addition to time to and amplitude of 
maximal clot formation. 
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2. Selected methods and materials 
Patients
Paper I 
Blood samples were collected from 18 persons with hereditary thrombophilia who had 
attended the Thrombosis Clinic, Aker University Hospital. Six were on warfarin treatment, 
(18-87 years, mean age 53). All of the patients on warfarin treatment had a history of VTE. Of 
the twelve persons not taking warfarin (25-69 years, mean age 41), six persons had previously 
sustained VTE. One person spontaneously developed VTE three months after this blood 
sampling. 
Blood samples were also obtained from 23 healthy controls (31-68 years, mean age 43) 
(health personnel at Aker University Hospital). 
Specific tests for AT, PC, PS and FV Leiden mutation were performed in all these plasma 
samples. 
Paper II 
Blood samples were collected from 24 persons with thrombophilia (14-71 years, mean age 
35) who had attended the Thrombosis Clinic, Aker University Hospital. Seven of them had 
previously sustained VTE. None of them were on warfarin medication. 
Blood samples were also collected from 24 normal controls (25-70 years, mean age 44) 
(health personnel and medical students at Aker University Hospital). 
Specific tests for AT, PC, PS and FV Leiden mutation were performed in all these plasma 
samples. 
Paper III 
Blood samples were obtained from 23 persons with thrombophilia. These persons were 
identical to the persons in Paper II. Blood samples were also obtained from 23 healthy 
controls. 16 of these persons were identical to the donors in Paper II. 
Specific tests for AT, PC, PS and FV Leiden mutation were performed in plasma from the 
additional controls included in the study. 
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Paper IV 
Blood samples were collected from 202 healthy postmenopausal women (45-65 years). None 
of them had a history of VTE. 
Specific tests for AT, PC, PS, FV Leiden and prothrombin gene mutation were performed in 
plasma from the persons included in the study. Twelve of them had heterozygous FV Leiden 
mutation and two had heterozygous prothrombin gene mutation. 
The CIP assay 
For each plasma sample analysed runs A and B were performed in triplicate. In both runs 
aliquots of 100 μl of citrated plasma were diluted with buffer. Run A is based on the OHP 
assays described by He et al [165]. In run B the snake venom Protac was added 5 min prior to 
and pentasaccharide immediately prior to recalcification, making their concentrations 0.15 
IU/ml and 1.1 μg/ml respectively. The reactions were started by adding TF (Innovin) (1.5 pM 
in Paper III and 0.67 pM in Paper IV), CaCl2 (17mM). Buffer was 66.0 mM Tris, 130.0 mM 
NaCl, pH 7.4. 
When thrombin 0.4 nM was used to trigger the reaction instead of TF (Paper I, II and III) 0.16 
IU/ml Protac and 1.2 μg/ml pentasaccharide were used. 
t-PA (440 ng/ml) was included in the assay in Paper I, II and III. 
The absorbance was measured at 405 nm in a Dynex MRX microplate reader at 37 °C every 
minute for 20 min. When t-PA was added the recording was 40 min to follow fibrinolysis. A 
curve was obtained by plotting absorbance against time. The AUC was calculated as the sum 
of these absorbance values. 
Inhibition was calculated by using the reduction of the AUC in run B relative to the result 
obtained in run A: ((A-B)/A) x 100, expressed in Units (U). 
The coefficient of variation (CV) for curves A and B in Paper II ranged 8.8 to 9.0% (intra–
assay) (n = 8) and 7.2 to 6.7% (inter–assay) (n = 8). 
In Paper III CV for curves A and B ranged 0.8 to 6.6% (intra–assay) (n = 8) and 3.6 to 12.4% 
(inter–assay) (n = 8) for normal controls. For persons with thrombophilia, the intra-assay CV 
ranged 2.0 to 2.3% (n = 8) and inter-assay CV ranged 4.2 to 5.4% (n = 8). 
In Paper IV CV for curves A and B ranged 1.8 to 6.9% (intra–assay) (n = 28) and 2.9 to 9.3% 
(inter–assay) (n = 28). 
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Statistical analysis 
P values < 0.05 were chosen as the level of statistical significance. 
Paper I 
Differences between the individual groups were analysed using the Mann-Whitney test. Data 
analysis was performed using the Minitab for Windows statistical software. 
Paper II 
Differences between two individual groups were analysed using the Mann-Whitney test. 
Receiver operating characteristic (ROC) curves were used for sensitivity and specificity 
analysis. The Pearson correlation coefficient was applied for correlation analysis. 
The statistical program package of social science (SPSS) version 11.0 was used for Mann-
Whitney and correlation analysis. SPSS, Stata/SE 8.0 and S-Plus statistical software were 
used for ROC curve analysis. 
Paper III 
Differences between two independent groups were analysed using the Mann-Whitney test. 
The Pearson correlation coefficient was used for correlation analysis. ROC curves were used 
for sensitivity and specificity analysis. SPSS version 11.0 was used for Mann-Whitney and 
correlation analysis. SPSS, Stata/SE 8.0 and S-Plus statistical software were used for ROC 
curve analysis. 
Paper IV 
Nonparametric tests were chosen because of markedly skewed efficacy variables. At baseline 
the individual groups were compared using the Kruskal-Wallis test. For each group the 
comparisons between baseline values and last visit were analysed using Wilcoxon signed rank 
test. Differences between two individual groups were analysed using the Mann-Whitney test. 
Correlation between two variables was expressed as Spearman rank correlation coefficient. 
Data analyses were performed using the SPSS version 13.0 and the Minitab for Windows 
statistical software. 
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3. Aims of the study 
The main aims of this study were 
1. To develop a global coagulation assay for use in routine laboratories that can detect the 
presence of hereditary thrombophilia. 
2. To evaluate our assay by testing different patient materials, including other conditions with 
an increased tendency to thrombosis. 
Specifically 
- Investigate to what extent addition of substances that potentiate endogenous coagulation 
inhibitors have on blood coagulation. These substances are reagents that mimic the effect of 
the normal endothelial cell. 
- Evaluate our assay by testing plasma samples with severe thrombophilia and compare it with 
other related published assays. 
-Analyse plasma samples from postmenopausal women before and after treatment with 
hormone therapy. 
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5. Brief summary of results 
Paper I 
Overall haemostasis potential assays performed in thrombophilic plasma: the effect of 
preactivating protein C and antithrombin. 
The “Overall Haemostasis Potential” (OHP I) assay for determination of the fibrin 
aggregation curve in plasma developed by He et al was tested to see if inheritable 
thrombophilia could be detected, particularly combined PS deficiency and heterozygous FV 
Leiden mutation. 
Plasma from persons with inherited thrombophilia and normal controls were analysed. The 
median OHP I values for the area under the opacity curve were very similar in thrombophilic 
samples and normal controls. The assay was therefore modified by enhancing inhibition of 
coagulation by adding Protac to activate PC and pentasaccharide to activate AT. Whereas the 
AUC in normal controls was reduced by the addition of Protac and pentasaccharide, the 
thrombophilic samples were not significantly affected by the addition of coagulation 
inhibitors. In the modified version of the assay the median value for AUC was significantly 
lower in normal controls compared with the group with thrombophilia (P = 0.035). 
The assay was also performed on plasmas from a small group of thrombophilia patients on 
warfarin treatment. Protac and pentasaccharide had little effect on samples from the warfarin 
treated thrombophilias. 
In the original OHP I assay, He et al had reported high AUC values in pregnancy and 
preeclampsia. Since PS is lowered and APC resistance is increased in these conditions, seven 
of the thrombophilic samples with combined PS deficiency and FV Leiden mutation were 
compared with normal controls. Their median AUC value in the OHP I assay was, however, 
not significantly different from the median level of the controls. 
Paper II 
The ability of three global plasma assays to recognize thrombophilia. 
“Coagulation Inhibitor Potential” (CIP) is a modified version of the OHP assay developed by 
He et al which is based on spectrophotometric registration of fibrin aggregation in plasma. We 
increased the sensitivity towards thrombophilia by adding reagents that potentiate the 
coagulation inhibitors in plasma. CIP measures the effect of adding Protac and 
pentasaccharide relative to the result obtained with the unmodified OHP assay. 
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Three different global clotting assays were compared in order to test their ability to detect 
different types of inherited thrombophilia. “Calibrated Automated Thrombogram” (CAT), 
“ProC Global” (PCG) and CIP were performed on plasma from normal controls and persons 
with inherited thrombophilia. 
The CAT monitors the generation of thrombin in clotting plasma using a fluorometer. The 
assay separated all plasma samples with AT deficiency, but was less sensitive to 
abnormalities in the PC system. In the PCG assay APTT clotting times are measured with and 
without APC which is activated by preincubation with Protac. PCG was more sensitive to 
abnormalities in the PC pathway. The median PCG value in thrombophilic samples was 
significantly lower compared with the median value of the healthy controls (P < 0.0001), but 
the assay did not detect AT deficiency and plasma from persons with PS deficiency had 
median value close to that of the healthy controls. The CIP assay was approximately equally 
sensitive to AT deficiency and defects in the PC system. The median CIP value in the 
thrombophilic group was significantly lower than in the control group (P < 0.0001). With the 
CIP assay ROC analysis showed that with a sensitivity of 100% the specificity was 87.5%. 
Paper III 
Coagulation Inhibitor Potential: a study of assay variables.
The purpose of this study was to optimise assay conditions in the CIP assay. TF was 
compared with thrombin as a trigger of coagulation in plasma samples from 20 persons with 
severe thrombophilia and 20 normal controls. The CIP assay detected different thrombophilic 
conditions equally well with TF and thrombin (r = 0.89, P < 0.0001). The addition of Protac, 
TM and pentasaccharide as accelerators of the inhibitors of coagulation was evaluated. The 
tested concentrations of Protac and TM increased the anticoagulant effect, but only in the 
presence of pentasaccharide. TM also reduced fibrinolysis. With pentasaccharide alone, 
coagulation was delayed in a dose-dependent manner. Pentasaccharide and Protac had a 
synergistic effect resulting in reduced coagulation in normal controls, but less in persons with 
thrombophilia. CIP was tested as a pure coagulation assay by omitting t-PA in attempt to 
reduce analysis time. Plasma samples from 23 thrombophilias were compared with 23 normal 
controls. The performance of the CIP assay was not decreased by omitting t-PA and CIP 
could therefore be used without t-PA in future analysis. 
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Paper IV 
Hormone therapy and raloxifene reduce the coagulation inhibitor potential.
The effect on CIP in plasma samples from postmenopausal women treated with conventional-
dose hormone therapy (HT), low-dose HT, the alternative drugs raloxifene, and tibolone was 
compared. HT is a combination of oestrogen and progestogen (see page 18). Use of HT and 
raloxifene are associated with an increased risk of venous thrombosis. The CIP assay was 
performed on plasma samples from 202 healthy women who were randomly assigned to 
receive treatment for twelve weeks treated with one of four different therapeutic regimens. 
Twelve women were heterozygous carriers of the FV Leiden mutation. Major thrombophilias 
were excluded. Fibrin aggregation in plasma was monitored after activation of coagulation 
with TF, and the effect of potentiated inhibition of coagulation was measured. 
Compared with baseline the median CIP value was reduced by 64% in the conventional-dose 
HT group, by 38% in the low-dose HT group, 31% in the raloxifene group, whereas for those 
treated with tibolone median CIP increased by 9%. These changes were significant for the two 
HT groups (P < 0.0001) and the raloxifene group (P = 0.003). Tibolone treatment did not 
significantly change the median CIP value. Women with heterozygous FV Leiden mutation 
had significantly reduced median CIP level (P < 0.0001) at baseline. 
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6. General discussion 
6.1 Development of the CIP assay 
Methodological considerations 
The major aim of this project was to develop a global screening test that could predict the 
presence of thrombophilia. Two existing assay methods were considered, as they were 
explicitly designed to reflect not only the activation, but also the control of coagulation. 
The CAT assay is the latest version of TG assay developed by HC Hemker [178]. It is 
technically advanced and requires specialised equipment. Thrombin is measured in plasma by 
the use of a fluorogenic substrate without subsampling. As thrombin is so central in the 
haemostatic process it could be of interest to use this enzymatic method to study conditions 
associated with thrombotic tendency. Two different versions of this assay with added APC 
and TM have been developed [190], but no single version could be used for the detection of 
the different forms of inherited thrombophilia. We considered the possibility to manipulate 
the assay principle in order to increase the sensitivity of the assay. This would be difficult, as 
the CAT assay employs advanced software required to compensate for the influence of low 
molecular weight substrates on the inhibitory reactions. 
We therefore decided to explore and to evaluate the OHP assay introduced by He et al 
[164,165]. This assay was described as a simple method to demonstrate a hypercoagulable or 
hypocoagulable state. In addition, the OHP assay can be performed with a temperature 
controlled ELISA reader. Results in plasma from persons with hereditary thrombophilia had 
not been reported at that time, but addition of AT had been shown to reduce the global 
activity [164]. 
Evaluation of the OHP method 
We tested plasma samples from normal controls and thrombophilic persons, but neither the 
OHP I nor II assays were sensitive to severe thrombophilia [Paper I]. In plasma from normal 
controls and also from thrombophilic persons the median AUC values were higher in the OHP 
I assay compared with the OHP II assay. This probably reflected that the higher thrombin 
concentration in OHP I contributed to fibrinogen concentration. Using the lower thrombin 
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concentration coagulation was delayed and this reduced the AUC value. This modification, 
however, did not increase the sensitivity towards thrombophilia [Paper I]. 
In the OHP assay the conversion of plasma fibrinogen into a fibrin gel resulting in increasing 
absorbance values is continuously monitored over time. Each absorbance value represents a 
fibrin level at the corresponding time point. The resulting AUC, expressed as the absorbance 
sum gives information about fibrin generation throughout the measurement period. 
We compared the AUC to the fibrinogen level and found a significant positive correlation in 
normal controls (r = 0.75, P = 0.001) and in thrombophilic persons (r = 0.805, P < 0.0001) 
(unpublished results). The median fibrinogen level was not significantly different in the two 
groups. The AUC values within the two groups varied considerably. 
He et al had reported that the median AUC level was increased in women with heart failure 
compared with the controls and that fibrinogen concentration correlated to the AUC values 
[165]. In a later study women with previous VTE with or without APC resistance had higher 
AUC values compared with the controls, but the AUC values were unrelated to the fibrinogen 
concentration [186]. 
Enhancing the inhibition 
Fluidity of the blood in the vascular system depends inter alia on the interaction between 
plasmatic inhibitors of coagulation and their accelerators present on the endothelial surface. 
Heparan sulphate accelerates the inhibitory activity of AT. TM binds thrombin which now 
activates PC. In an attempt to increase the sensitivity of the fibrin aggregation assay we added 
reagents that mimic these endothelial accelerators. 
The snake venom Protac is a fast-acting PC activator. The pentasaccharide is a copy of the 
heparin sequence which binds to and activates AT. Binding of the pentasaccharide to AT 
induces a conformational change which results in an accelerated inhibition of FXa by AT. The 
pentasaccharide is not a thrombin inhibitor because it is too short to bridge AT to thrombin. 
This implies that only activity of TG will be enhanced. In contrast to heparin, pentasaccharide 
does not react with platelet factor 4 which may be present in different concentrations in 
plasma samples. For these reasons, pentasaccharide was chosen as an accelerator of AT. 
Protac and pentasaccharide both exerted anticoagulant effects when added to plasma in our 
test system. This effect was more pronounced in normal plasma than in thrombophilic plasma. 
With the addition of Protac and pentasaccharide we obtained markedly lower AUC median 
levels in the normal controls, but only slightly lower in the thrombophilic group [Paper I]. 
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The OHP and modified OHP assay was later developed into the Coagulation Inhibitor 
Potential (CIP) assay. In the CIP assay the effect of added Protac and pentasaccharide was 
measured relative to the result obtained with the unmodified assay. With the CIP assay an 
improved separation between normal controls and thrombophilias could thus be obtained. A 
weaker inhibitory response in thrombophilic plasma samples contrasted with results in normal 
controls. The inhibitory effect in the control group varied considerably [Paper II] and the 
reason for this is as yet unknown. 
We described the effect of enhancing the coagulation inhibitors in Paper III. Pentasaccharide 
alone delayed the coagulation in a dose dependent manner. In the CIP assay we used 1.2 μg 
pentasaccharide per ml plasma when thrombin was used as a trigger. When Protac was added 
alone (0.16 IU/ml) this unexpectedly caused an increase in AUC. The reason for this is 
probably due to an effect on fibrin polymerisation. Additions of higher doses Protac however, 
resulted in decreased AUC (unpublished results). Together Protac and pentasaccharide had a 
synergistic effect, even with lower Protac concentrations, demonstrated by reduced AUC 
levels in normal plasma samples. The concentrations of Protac and pentasaccharide were 
chosen to obtain a balanced effect of both inhibitory pathways. 
As an alternative to Protac we added TM. Human TM alone did not affect the coagulation in 
our assay [Paper III]. Rabbit TM, which may be a better activator of human PC [191] and 
pentasaccharide together increased delay more than pentasaccharide alone. Rabbit TM also 
inhibited fibrinolysis in reactions where t-PA was added. This may be due to the activation of 
thrombin activable fibrinolysis inhibitor (TAFI) [192]. TM was more expensive and 
apparently Protac was as useful in the assay. 
The CIP assay was performed at 37 ºC to ensure optimal conditions for the various enzymatic 
reactions. We have later tested plasma samples from normal controls and persons with 
thrombophilia at 27 ºC, but this did not change the results (unpublished results). This 
suggested that the CIP assay may be performed without a temperature controlled ELISA 
reader.
The choice of trigger 
We compared TF with thrombin as a trigger of coagulation [Paper III]. The addition of a 
small amount of exogenous thrombin sufficient to trigger the activation of coagulation via a 
feedback effect was originally used in the CIP assay. With TF (1.5 pM) we obtained similar 
reaction curves as with thrombin (0.04 IU/ml). The results from 20 normal controls and 20 
persons with thrombophilia indicated that TF was equally suited as thrombin as a trigger of 
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coagulation. Theoretically this is an advantage because TF is the biological trigger of 
coagulation which is initiated when TF binds to FVIIa in plasma. 
Fibrinolysis
The CIP assay was initially used as a combined assay that reflected both fibrin generation and 
fibrinolysis by the addition of t-PA, in the same way as the OHP assays. After addition of t-
PA, plasminogen is converted into plasmin, which digests fibrin into soluble fragments. 
Polymeric fibrin increases the catalytic property of t-PA [193]. During fibrin generation and 
accumulation of the fibrinolytic breakdown products the accelerated fibrinolytic process led to 
a decline in the absorbance values. 
We found that the sensitivity of the CIP assay to thrombophilia was not decreased by omitting 
t-PA as a reagent [Paper II]. Although plasminogen deficiency has been described as a rare 
cause of thrombophilia, abnormal fibrinolysis is probably seldom the cause of inherited 
thrombophilia. Omitting t-PA had the practical advantage that analysis time was reduced from 
40 to 20 minutes. 
In other situations, e.g. postoperatively, low fibrinolytic activation may be important for 
development of thrombosis. In some clinical situations, it might be interesting to include 
fibrinolysis in the assay. Although the CIP assay routinely can be used as a pure coagulation 
assay, alternatively, the fibrinolytic process can be included by the addition of t-PA. 
Expression of results 
For each plasma sample tested the CIP assay compares run A and run B. The area under the A 
curve (A value) did not separate thrombophilias from normal controls (Table 2). In run B 
coagulation was inhibited by the addition of Protac and pentasaccharide. Thus, the area under 
the B curve (B value) was decreased compared with the A value. This was distinct in normal 
plasma samples but not in thrombophilic plasma samples. 
Table 2. Ways of expressing the results with the CIP assay. Median values for 24 normal 
controls and 24 thrombophilias [Paper II]. Inhibition: ((A-B)/A) x 100
 A B (A-B) Inhibition 
Normal controls 162.7 68.2 101.4 55.5 
Thrombophilia 190.5 143.4* 34.8* 17.3* 
Overlapping 46/48 11/48 10/48 3/48 
*(P<0.0001) as compared with healthy controls 
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Three different possibilities for expressing the results existed. The simplest way would be to 
report the B value. Although the median B value for normal controls was about half of the 
median B value in the thrombophilia group, almost half of the normal controls had values that 
overlapped with the thrombophilic group (Table 2). 
The difference between A and B values obtained by the subtraction of A-B separated normal 
controls and thrombophilias better (Table 2). Yet, the overlap between the normal controls 
and the thrombophilia group was considerable. Ten of the 24 normal controls had values 
within the range of the thrombophilic group. 
The inhibition was calculated as ((A-B)/A) x 100 where A is the AUC in the absence and B 
the AUC in the presence of potentiated inhibition. This separated the normal controls and the 
thrombophilia group better than by using the subtraction of A-B or the B curve. Now, three 
out of 24 normal controls had CIP values that were within the thrombophilic area (Table 2). 
We thus concluded that inhibition was the best parameter to separate severe thrombophilias 
from normal controls. The A value is influenced both by the fibrinogen level and the level of 
the coagulation factors in the plasma samples. Expressing the results as inhibition, where 
value A is present both in the nominator and denominator reduces the influences of varying 
coagulation factor levels. 
In Paper I, II and III degree of inhibition was given in percent. In Paper IV we introduced 
units (U) to avoid confusion with other figures given in percent. In future work we will stick 
to reporting inhibition in Units. 
6.2 Comparison of three global assays 
Performance of the CIP assay 
Our results with the CIP assay suggested relatively high sensitivity with an apparently 
acceptable specificity. Of the 24 normal controls, three of them had values within the range of 
the 24 thrombophilic persons [Paper II]. Setting sensitivity to 100% the specificity was 
87.5%. High sensitivity in a global screening test for thrombophilia is important. In case of a 
pathological CIP value, specific tests for the different hereditary thrombophilias can then be 
used for further testing to decide a thrombophilic state. 
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In paper III five of the 23 controls had values within the range of the 23 thrombophilias both 
in the absence and presence of t-PA. With a sensitivity of 100% we thus obtained a specificity 
of 78%. 
The reason for low inhibition in a normal control may be due to unexplained thrombophilia. 
Clinically, even familial thrombophilia may exist even though this has not been confirmed by 
any of the specific tests available. 
Our results so far indicated that with the CIP assay we may obtain low inhibition in plasma 
samples from the majority of persons with AT, PC and PS deficiency and combined 
thrombophilias [Paper I, II and III]. 
We decided to compare CIP with the other global assays that are sensitive to hereditary 
thrombophilia. 
Performance of the PCG assay 
The PCG assay was designed to evaluate the functionality of the PC pathway. The assay is 
based on the ability of Protac to prolong the APTT in plasma by the activation of endogenous 
PC.
We confirmed that the PCG assay was sensitive to the homozygous FV Leiden mutation, and 
heterozygous FV Leiden in combination with AT or PS deficiency. PC deficiency was also 
detected by this assay, whereas persons with PS and AT deficiencies were not identified 
[Paper II]. The median CIP values obtained for PS and AT deficiencies were very similar. 
Other larger studies have confirmed that PCG is a reliable method for the detection of PC and 
combined deficiencies [194,195]. Also low sensitivity for PS by this test has been reported in 
other studies [194,195]. A further limitation is that AT is not detected by this method. 
Heterozygous FV Leiden mutation has been detected with 100% sensitivity in other studies 
[194-196], but was not tested in our study. 
A main advantage of PCG is that it is a simple method that also can be performed with an 
automated coagulation analyser available in any laboratory. 
Performance of the CAT assay 
In the CAT assay the TG in clotting plasma was measured by monitoring the splitting of a 
fluorogenic thrombin substrate. In our study we showed that with the CAT assay TG was 
increased in AT deficiency and thus separated from the control group even though the 
variability in the control group was large [Paper II]. The assay was much less sensitive to 
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deficiencies in the PC pathway. The TG in samples from persons with FV Leiden mutation, 
PS deficiency and PS deficiency in combination with FV Leiden mutation varied 
considerably. 
In addition to high TG in AT deficiency [197], carriers of the prothrombin gene mutation are 
also found to have increased TG [198]. 
A modified version of the TG assay with added APC made the assay sensitive to FV Leiden 
mutation in addition to PS deficiency, but did not reflect AT and PC deficiency [199]. 
Recently, a version of CAT with added TM to activate PC decreased TG in plasma samples 
from persons with thrombophilia. A significant resistance to the inhibitory effect of TM was 
found in plasma samples from persons with PC and PS deficiency as well as FV Leiden 
mutation and combined abnormalities [200]. Large variation in the control group resulted in 
overlap with the patient groups and made the assay in its present form not suited as a 
screening test for prothrombotic risk factors. 
The CAT method is technically demanding and software is required to convert fluorescence 
changes into thrombin concentration. The advantage of a fluorescent substrate compared with 
chromogenic substrate was that the optical turbidity due to fibrin formation did not disturb the 
fluorescent signal and the need for defibrination was abolished. This influenced the TG since 
thrombin is formed in a different manner in the presence and absence of fibrin. Moreover, the 
presence of fibrinogen attenuates the formation of Į2-macroglobulin-thrombin. 
6.3 Further studies on thrombophilia 
Although the CIP was superior in the comparison of the three global assays, the thrombophilic 
subgroups examined were too small for definite conclusions to be drawn and a further 
evaluation in larger materials was needed. Also the control group was small. 
In two ongoing studies we have performed the CIP assay in plasma samples from persons 
with defined thrombophilia. In collaboration with Professor Dr. Hajna Losonczy and Dr. 
Orsolya Toth, University of Pecs, Hungary we have analysed plasma samples from 71 persons 
with hereditary thrombophilia. We have also analysed 21 samples from persons with AT 
deficiency, twelve of them from persons on oral anticoagulants (OAC). These samples were 
obtained from Professor Dr. Jacqueline Conard, Hôtel Dieu hospital in Paris, France. 
The so far the largest normal material analysed with the CIP assay was samples from 188 
normal postmenopausal women included in the RET study [Paper IV] (Figure 6). That study 
additionally included samples from twelve women with heterozygous FV Leiden mutation. 
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Figure 6. Distribution of CIP (U) values obtained in samples from 188 normal 
postmenopausal women included in the RET study.
The results so far can be summarised as follows (Figure 7): 
The median CIP levels in the AT, PC and PS deficiency groups were significantly lower 
compared with the RET control group (P < 0.0001, P = 0.001 and P < 0.0001, respectively) 
(Table 4). 
The CIP values obtained in samples from persons with heterozygous FV Leiden were within 
the range obtained in the heterozygous FV Leiden group in Paper IV. 
We obtained a median CIP value in the heterozygous G20210A mutation group that was very 
similar to the median CIP level obtained in the RET controls (61 U). 
Even though LA is associated with an increased risk for thrombosis the median CIP level was 

















































Figure 7. Distribution of CIP (U) values obtained in samples from persons with 
thrombophilia: AT deficiency (n = 9), PC deficiency (n = 5), FV Leiden, heterozygous (n = 
15), PC + other thrombophilic condition (n = 9), PS + other thrombophilic condition (n = 7), 








































Table 4. Median (range) CIP values obtained in samples from normal women, persons 
with single thrombophilia states and LA. 




Controls, (RET) 188 0 61 (-10 – 100) 
AT deficiency 9 2 15 (-5 – 38) 
PC deficiency 5 5 15 (3 – 23) 
PS deficiency 13 8 21 (-11 – 43) 
FV Leiden, heteroz 3 3 3 (3 – 29) 
FV Leiden, heteroz, (RET) 12 0 -6 (-19 - 36) 
G20210A, heteroz 14 11 59 (6 – 98) 
LA 11 7 72 (34 – 98) 
The median CIP level in persons with a single thrombophilia (AT, PS, PC deficiency and 
heterozygous FV Leiden) (14 U), were higher compared with the persons with combined 
thrombophilias (4 U), but the difference were not significant (P = 0.058) (Table 5). These 
results suggested that combined thrombophilias are well detected with the CIP assay. 
Table 5. Median (range) CIP values obtained in samples from persons with combined 
thrombophilias.




PC deficiency + other 9 7 1 (-17 – 13) 
PS deficiency+ other 7 7 -2 (-23 – 25) 
FV Leiden heteroz +  
G20210A, heteroz 
9 8 14 (-9 – 40) 
Sensitivity and specificity: 
Based on the results from the RET study, Pecs study and the collaboration with Paris ROC 
analyses could be used to find sensitivity and specificity (Table 6). 
The highest sensitivity and specificity were obtained in the groups with PC deficiency and 
combined PC and PS deficiencies followed by the group with AT deficiency. 
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Table 6. Sensitivity, specificity and cut off values obtained with the CIP assay in 
different thrombophilic states. 
Thrombophilia N Sens % Spec % Cut off (U) 
AT 9 100 79 38 
PC, PC + other, PS + other 21 100 88 25 
PS, FV Leiden, 
FV Leiden + G20210A 
25 100 75 43 
PS, FV Leiden, 
FV Leiden + G20210A 
25 84 80 34 
6.4 Influence of warfarin on CIP 
Warfarin therapy reduces vitamin K dependent coagulation factors and changes the 
haemostatic balance. Anticoagulant therapy with warfarin protects persons with severe 
thrombophilia as it decreases the risk for VTE. 
Findings in Paper I suggested that abnormal results with the CIP test may be obtained in 
persons with AT and PC deficiency even when on warfarin therapy. This topic has now been 
explored in more detail. 
We obtained plasma samples from persons with AT deficiency on OAC and samples from 
persons without thrombophilia but on OAC (Table 7) from J. Conard in Paris. Increasing INR 
values correlated significantly with delayed initiation of coagulation in samples from persons 
taking OAC (r = 0.86, P < 0.0001). The median CIP value in the AT deficiency group on 
OAC were higher compared with the AT deficiency group not taking OAC, but the difference 
were not significant (P = 0.382). 
Table 7. Median (range) CIP values obtained in samples from persons on OAC.




Controls 4  51 (35 – 61) 
AT 12 12 23 (0 – 90) 
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6.5 Influence of oestrogen-progesterone, raloxifene and tibolone on CIP 
In Paper IV we wanted to see if CIP could reflect changes in coagulation related to the use of 
medication that may increase the risk of VTE. Plasma samples from postmenopausal women 
treated with four different therapeutic regimens used to prevent osteoporosis and other ill 
effects of the menopause were compared. 
The most distinct reduction in median CIP was found in the women treated with 
conventional-dose oestrogen-progestogen (2 mg 17ȕ-estradiol + 1 mg norethisterone acetate 
(NETA)) and low-dose oestrogen-progestogen (1 mg 17ȕ-estradiol + 0.5 mg NETA). A lower 
median CIP value in the conventional-dose oestrogen-progestogen group compared with the 
women treated with low-dose oestrogen-progestogen suggested a dose-response effect, but 
this difference was not statistically significant (P = 0.111). The changes in the median CIP 
values were caused mainly by increased B values, although a moderate decrease in the A 
value in the conventional-dose oestrogen-progestogen group was also found. The A-B median 
values were thus reduced (Figure 8). This confirmed that the AT and PC pathways are 
affected by this treatment [146]. In a study based on the same women material and in other 
studies the use of oestrogen-progestogen reduced the sensitivity to APC [145,201,202], which 
is a known risk factor for VTE [131]. 
Raloxifene also reduced median CIP, but less than oestrogen-progestogen. The median A-B 
value was also lowered. The change in CIP was caused both by an increase in the B values 
and by a decrease in the A values. The reduction in the A values may be explained by reduced 
level of fibrinogen. Fibrinogen concentration was reduced after use of raloxifene in a study 
based on the same women material [146]. In that study it was also shown that AT, PC and 
TFPI levels decreased, whereas FVIII activity levels increased after raloxifene treatment. 
Additionally, raloxifene also reduced sensitivity to APC [202]. Previous studies have reported 
decreased AT activity and increased FVIII levels [203-205] as well as reduced sensitivity to 
APC [206] after treatment with raloxifene. 
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Figure 8. Change in median values (%) from baseline to last visit for A and B values, A-
B values and Inhibition: ((A – B)/A)) x 100 in the conventional-dose (conv-dose) and low-
dose oestrogen-progestogen group, raloxifene and tibolone group.
We found that tibolone did not appear to affect inhibition of coagulation significantly. In a 
previous study based on the same women material it has been suggested that tibolone does not 
affect the sensitivity to APC [202]. In another previous study, AT and PC levels decreased, 
whereas PS levels and TFPI activity increased after tibolone treatment [146]. So far tibolone 
has not been found to increase the risk of VTE, but more data are needed. An increased 
incidence of stroke, however, has recently been reported [150]. 
These results suggested that in this study expression of the results as subtraction of A-B could 
be an alternative to inhibition (Figure 8). The B value did not separate the change in median 
CIP in the two oestrogen-progestogen groups. A change in A value caused by the treatment 
may be of importance for the result, but would not be reflected when only the B value is used. 
B A-B ((A-B)/A))*100


























We have analysed plasma samples from six women who used oral contraceptives (OC) 
(unpublished results). The CIP assay, with thrombin as a trigger and added t-PA resulted in 
low inhibition between 3 U and 17 U. The median CIP value in the thrombophilia group 
tested in Paper II was 17.3 (Table 2). OC use is associated with a decrease in PS and AT 
[132].
In conclusion, conventional oestrogen-progestogen and raloxifene treatment as well as use of 
OC increase the risk of VTE. These results suggest that also the presence of acquired risk 
factors for venous thrombosis might be detected with the CIP assay. 
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7. Main conclusions 
1. An assay method described by He et al was tested to se if it could be used to detect 
inherited thrombophilia. As the median levels for the area under the fibrin 
polymerisation curve in plasma samples from normal controls and persons with 
thrombophilia were similar, this method did not detect inherited thrombophilia. 
2. The original assay was modified by adding Protac to activate protein C and 
pentasaccharide to activate antithrombin. Inhibition of coagulation was enhanced in 
normal plasma samples, but only slightly in samples from persons with inherited 
thrombophilia. 
3. We developed the Coagulation Inhibitor Potential (CIP) assay. Inhibition is measured 
in Units as ((A-B)/A) x 100 where A is the area under curve in the absence, and B in 
the presence of Protac and pentasaccharide. 
4. Three global plasma assays were compared to test their ability to recognise inherited 
thrombophilia. The CIP assay performed better than the Calibrated Automated 
Thrombogram and the ProC Global assay. 
5. The CIP assay performed equally well with tissue factor and thrombin as triggers of 
coagulation.
6. The performance of the CIP assay was not decreased by omitting fibrinolysis. 
7. Median CIP levels were reduced in plasma samples from healthy postmenopausal 
women treated with oestrogen-progesterone and raloxifene. Oestrogen-progestogen
and raloxifene use are associated with increased risk of venous thrombosis. 
8. Plasma samples from postmenopausal women taking tibolone did not have reduced 
median CIP level. 
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Errata
Paper I, page 326, Table 4: Median controls, Difference should read: 34.0. 
Paper II, page 414, legend Fig. 1. First line should read: Individual values of the CAT assay. 
Paper III, page 522, Figure 2 A: Two experimental values in the control group are missing. 
These are: 90% and 99% inhibition. (The median value (horizontal line) is correct). 
Paper IV, page 456, Statistics, bottom line should read: …(five cases) were used instead. 

